SG11201805906WA - Diagnostic and prognostic methods for cardiovascular diseases and events - Google Patents

Diagnostic and prognostic methods for cardiovascular diseases and events

Info

Publication number
SG11201805906WA
SG11201805906WA SG11201805906WA SG11201805906WA SG11201805906WA SG 11201805906W A SG11201805906W A SG 11201805906WA SG 11201805906W A SG11201805906W A SG 11201805906WA SG 11201805906W A SG11201805906W A SG 11201805906WA SG 11201805906W A SG11201805906W A SG 11201805906WA
Authority
SG
Singapore
Prior art keywords
international
washington
events
pct
applicant
Prior art date
Application number
SG11201805906WA
Inventor
Rhonda Fay Rhyne
Craig Agamemnon Magaret
John Edward Strobeck
James Louis Januzzi Jr
Original Assignee
Prevencio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevencio Inc filed Critical Prevencio Inc
Publication of SG11201805906WA publication Critical patent/SG11201805906WA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4884—Other medical applications inducing physiological or psychological stress, e.g. applications for stress testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B6/00—Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
    • A61B6/50—Clinical applications
    • A61B6/503—Clinical applications involving diagnosis of heart
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization 111111110111101110101011111 HO 11111 011101110011001111100111 111E1111 MI International Bureau ... .... ..Yjd (10) International Publication Number (43) International Publication Date ..... ...r .....1 WO 2017/136464 Al 10 August 2017(10.08.2017) WIPO I PCT (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every G01N 33/68 (2006.01) A61B 5/02 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, PCT/US2017/016081 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, 1 February 2017 (01.02.2017) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, (25) Filing Language: English NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (26) Publication Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (30) Priority Data: ZA, ZM, ZW. 62/289,513 1 February 2016 (01.02.2016) US 62/378,535 23 August 2016 (23.08.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PREVENCIO, INC. [US/US]; 11335 NE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, 122nd Way, Suite 105, Kirkland, Washington 98034 (US). TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (72) Inventors: RHYNE, Rhonda Fay; 6424 Lake Washington TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Blvd NE, #13, Kirkland, Washington 98033 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, MAGARET, Craig Agamemnon; 2534 NE 83rd Street, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Seattle, Washington 98115 (US). STROBECK, John Ed- GW, KM, ML, MR, NE, SN, TD, TG). — ward; 59 West Saddle River Road, Saddle Ridge, New Jer- — sey 07458 (US). JANUZZI, James Louis Jr.; 83 Pilgrim Declarations under Rule 4.17: _ = Road, Wellesley, Massachusetts 02481 (US). — — as to applicant's entitlement to apply for and be granted a (74) Agents: SHERIN, Mridula P. et al.; Cooley LLP, 1299 patent (Rule 4.1700) Pennsylvania Avenue, NW, Suite 700, Washington, Dis- trict of Columbia 20004 (US). = = [Continued on next page] (54) Title: DIAGNOSTIC AND PROGNOSTIC METHODS FOR CARDIOVASCULAR DISEASES AND EVENTS = = (57) : Compositions and methods = are provided for diagnosis and/or prognos - Figure 1 is of cardiovascular diseases or events in a = -- subject. In some embodiments, the method = __ = = = E = g J s to = = _ E 1-- _ 1-1 __ includes measuring and comparing the level of particular proteins to other pro- teins. In other embodiments, the method includes comparison with clinical variable information. .4 4 € € 0.0 02 OA O6 OA 1,0 71' False poslfive rate 71' (MC . 0,872) M Il IN Il 0 ei O WO 2017/136464 Al 1#1101MOMOIDEIROIDEDE111101100111100IMMOVOIS — as to the applicant's entitlement to claim the priority of Published: the earlier application (Rule 4.17(iii)) — with international search report (Art. 21(3))
SG11201805906WA 2016-02-01 2017-02-01 Diagnostic and prognostic methods for cardiovascular diseases and events SG11201805906WA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662289513P 2016-02-01 2016-02-01
US201662378535P 2016-08-23 2016-08-23
PCT/US2017/016081 WO2017136464A1 (en) 2016-02-01 2017-02-01 Diagnostic and prognostic methods for cardiovascular diseases and events

Publications (1)

Publication Number Publication Date
SG11201805906WA true SG11201805906WA (en) 2018-08-30

Family

ID=59500904

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201805906WA SG11201805906WA (en) 2016-02-01 2017-02-01 Diagnostic and prognostic methods for cardiovascular diseases and events

Country Status (13)

Country Link
US (3) US10983135B2 (en)
EP (1) EP3411720A4 (en)
JP (3) JP7134870B2 (en)
KR (1) KR20180101595A (en)
CN (2) CN114441773A (en)
AU (1) AU2017214469A1 (en)
BR (1) BR112018015698A2 (en)
CA (1) CA3012192A1 (en)
MA (1) MA43980A (en)
MX (1) MX2018009304A (en)
RU (1) RU2018130866A (en)
SG (1) SG11201805906WA (en)
WO (1) WO2017136464A1 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017136464A1 (en) 2016-02-01 2017-08-10 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events
EP4296678A2 (en) * 2017-09-14 2023-12-27 Laboratory Corporation of America Holdings Assessing myocardial infarction and serious infection risk in rheumatoid arthritis patients
WO2019090166A1 (en) * 2017-11-02 2019-05-09 Prevencio, Inc. Diagnostic and prognostic methods for peripheral arterial diseases, aortic stenosis, and outcomes
CN110232975A (en) * 2019-05-20 2019-09-13 郑州大学第一附属医院 A kind of pair of method that renal replacement therapies risk profile is entered in Diabetic Nephropathy patients 3 years
CN110491512A (en) * 2019-08-08 2019-11-22 郑州大学第一附属医院 A kind of pair of Renal biospy makes a definite diagnosis the method that End-stage renal disease risk profile is entered in Diabetic Nephropathy patients 3 years
CN110596399B (en) * 2019-08-29 2022-07-22 首都医科大学附属北京安贞医院 Application of substance for detecting content of angiopoietin-like protein8
CN110970131B (en) * 2019-10-24 2024-01-26 中国医科大学附属盛京医院 Glomerular disease classification parting model based on immunoglobulin quantitative detection and application thereof
RU2726314C1 (en) * 2019-11-15 2020-07-14 Федеральное государственное бюджетное образовательное учреждение высшего образования "Тихоокеанский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for early prediction of acute renal injury in patients with coronary heart disease following myocardial revascularization by coronary artery bypass grafting
RU2760445C1 (en) * 2020-11-13 2021-11-25 Виталий Юрьевич Мишланов Method for diagnosing pathological human conditions
WO2022202360A1 (en) * 2021-03-23 2022-09-29 テルモ株式会社 Information processing device, information processing method, and program
CN113342963B (en) * 2021-04-29 2022-03-04 山东大学 Service recommendation method and system based on transfer learning
RU2770550C1 (en) * 2021-05-31 2022-04-18 Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Method for predicting cardiovascular risk by determining the level of estrogens
WO2023192004A2 (en) * 2022-03-30 2023-10-05 Inflammatix, Inc. Methods for diagnosing myocardial infarction
CN115185936B (en) 2022-07-12 2023-02-03 曜立科技(北京)有限公司 Medical clinical data quality analysis system based on big data
CN114974576A (en) * 2022-07-12 2022-08-30 曜立科技(北京)有限公司 Cardiovascular and cerebrovascular disease diagnosis and management system based on metadata

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20080202927A1 (en) 2000-11-03 2008-08-28 Clinical Micro Sensors, Inc. Devices and methods for biochip multiplexing
US20060228723A1 (en) 2002-01-16 2006-10-12 Keith Bradley System and method for electronic sensing of biomolecules
US20030134433A1 (en) 2002-01-16 2003-07-17 Nanomix, Inc. Electronic sensing of chemical and biological agents using functionalized nanostructures
US9234867B2 (en) 2003-05-16 2016-01-12 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
US8685711B2 (en) 2004-09-28 2014-04-01 Singulex, Inc. Methods and compositions for highly sensitive detection of molecules
WO2006089226A1 (en) * 2005-02-17 2006-08-24 University Of Florida Research Foundation, Inc. β-BLOCKER PHARMACOGENETICS IN HEART FAILURE
CN101495862A (en) * 2005-06-24 2009-07-29 利兰·斯坦福青年大学托管委员会 Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
US8093017B2 (en) * 2005-12-07 2012-01-10 Siemens Heathcare Diagnostics Inc. Detection of soluble adiponectin receptor peptides and use in diagnostics and therapeutics
US20100331200A1 (en) * 2006-03-31 2010-12-30 Gordon Neal F Post translational modification pattern analysis
EP2924440A3 (en) * 2006-06-07 2016-03-09 Health Diagnostic Laboratory, Inc. Markers associated with arteriovascular events and methods of use thereof
WO2008045799A2 (en) 2006-10-06 2008-04-17 Nanomix, Inc. Electrochemical nanosensors for biomolecule detection
EP2084543B1 (en) 2006-10-26 2017-10-18 B.R.A.H.M.S GmbH Risk stratification for acute coronary syndrome by means of fragments/partial peptides of provasopressin, especially copeptin or neurophysin ii
CA2697357A1 (en) 2007-04-16 2008-10-30 John T. Mcdevitt Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
GB0717637D0 (en) 2007-09-10 2007-10-17 Univ Leiden Future cardiac event biomarkers
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
EP2437652A1 (en) 2009-06-04 2012-04-11 Koninklijke Philips Electronics N.V. Method and system for providing behavioural therapy for insomnia
WO2010144358A1 (en) 2009-06-08 2010-12-16 Singulex, Inc. Highly sensitive biomarker panels
EP2467720A1 (en) * 2009-08-20 2012-06-27 The Board of Regents of The University of Texas System Methods and compositions for diagnosis of acute myocardial infarction (ami)
CN102762743A (en) * 2009-12-09 2012-10-31 阿维埃尔公司 Biomarker assay for diagnosis and classification of cardiovascular disease
KR101256928B1 (en) * 2010-01-20 2013-04-19 주식회사디엔에이링크 Single Nucleotide Polymorphisms Implicated in Obesity or Diabetes and Use Thereof
WO2012120387A1 (en) 2011-03-09 2012-09-13 Abionic Sa Rapid quantification of biomolecules in a selectively functionalized nanofluidic biosensor and method thereof
WO2012145037A1 (en) 2011-04-19 2012-10-26 Scott & White Healthcare Novel apoc-i isoforms and their use as biomarkers and risk factors of atherosclerotic disease
US20140011811A1 (en) * 2011-10-06 2014-01-09 The United States Government As Represented By The Department Of Veterans Affairs Myosin binding protein-c for use in methods relating to diastolic heart failure
US11450431B2 (en) * 2012-11-16 2022-09-20 Siemens Healthcare Gmbh Method to identify optimum coronary artery disease treatment
EP3019873A1 (en) 2013-07-12 2016-05-18 Emory University Diagnostic assay to predict cardiovascular risk
EP3021968B1 (en) 2013-07-17 2018-09-26 Abionic SA Method and device for bioassays
WO2015085314A2 (en) * 2013-12-06 2015-06-11 Diadexus, Inc. Methods for detection of heart failure
US10509044B2 (en) * 2014-05-08 2019-12-17 University Of Maryland, Baltimore Methods for assessing differential risk for developing heart failure
US10434508B2 (en) 2014-07-03 2019-10-08 Abionic Sa Capsule for rapid molecular quantification of a fluid sample such as whole blood
WO2017136464A1 (en) 2016-02-01 2017-08-10 Prevencio, Inc. Diagnostic and prognostic methods for cardiovascular diseases and events

Also Published As

Publication number Publication date
MX2018009304A (en) 2019-01-10
JP7134870B2 (en) 2022-09-12
EP3411720A4 (en) 2019-08-14
US10983135B2 (en) 2021-04-20
BR112018015698A2 (en) 2018-12-26
JP2022171936A (en) 2022-11-11
CA3012192A1 (en) 2017-08-10
EP3411720A1 (en) 2018-12-12
MA43980A (en) 2018-12-12
RU2018130866A (en) 2020-03-04
US20190369120A1 (en) 2019-12-05
US11977083B2 (en) 2024-05-07
JP2019507354A (en) 2019-03-14
JP2021128177A (en) 2021-09-02
KR20180101595A (en) 2018-09-12
US20210072260A1 (en) 2021-03-11
CN114441773A (en) 2022-05-06
AU2017214469A1 (en) 2018-07-26
CN108700596A (en) 2018-10-23
US20230341418A1 (en) 2023-10-26
WO2017136464A1 (en) 2017-08-10
JP7403498B2 (en) 2023-12-22

Similar Documents

Publication Publication Date Title
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201904942YA (en) Blockchain-based service execution method and apparatus, and electronic device
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201901834WA (en) Micrornas as biomarkers for endometriosis
SG11201811740WA (en) Systems and methods for identifying risky driving behavior
SG11201909160WA (en) Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
SG11201910019PA (en) Microorganisms and methods for producing cannabinoids and cannabinoid derivatives
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201908743SA (en) Methods and compositions for modulation of immune cells
SG11201906413XA (en) Exposure apparatus
SG11201906778RA (en) Improved methods for assessing risk of developing breast cancer
SG11201908767QA (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging
SG11201807281TA (en) Polyethylene composition, method of making the same, and films made therefrom
SG11201811550XA (en) Demand prediction for time-expiring inventory
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201807719SA (en) Use of clinical parameters for the prediction of sirs
SG11201903602RA (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
SG11201809793UA (en) Tl1a antibodies and uses thereof
SG11201809474TA (en) Compositions and methods for bioengineered tissues
SG11201906313SA (en) A polypeptide linker for preparing multispecific antibodies
SG11201900912PA (en) Novel fish pathogenic virus
SG11201407208UA (en) A method for dynamic generation and modification of an electronic entity architecture